A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other...

Area of Science:

• Pharmacogenomics
• Clinical Pharmacology
• Genetics

Background:

• Warfarin dosing is influenced by clinical factors and genetic variations.
• Existing pharmacogenetic algorithms have not fully assessed the impact of genotypes associated with warfarin resistance.
• Accurate warfarin dosing is critical for effective anticoagulation and minimizing bleeding risks.

Purpose of the Study:

• To develop and evaluate a novel warfarin dosing algorithm for the Italian population.
• The algorithm incorporates genetic polymorphisms linked to both warfarin sensitivity and resistance.
• To compare the performance of the new algorithm against eight previously published dosing algorithms.

Main Methods:

• Developed a new dosing algorithm using clinical and genetic data, including CYP2C9*2, CYP2C9*3, VKORC1 -1639 G > A, and VKORC1 3730 G > A.
• Utilized derivation (n=55) and validation (n=40) patient groups on stable oral anticoagulation therapy.
• Compared algorithm performance using Mean Absolute Error (MAE), dose correlation, and R² values.

Main Results:

• The new algorithm's performance was comparable or slightly superior to existing algorithms.
• It accurately assigned 53.3%, 50.0%, and 57.1% of patients to low, intermediate, and high warfarin dose ranges, respectively.
• Demonstrated a significant improvement in predictive accuracy for patients requiring high warfarin doses.

Conclusions:

• The developed algorithm, including the VKORC1 3730 G > A polymorphism, enhances warfarin dosing.
• It allows for more precise identification of warfarin-resistant patients who need higher dosages.
• This contributes to improved warfarin management through pharmacogenetics.